Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Vasopressin for Renal Outcomes in Septic Shock
NCT06471231Phase 4Recruiting
- Sponsor
- Azienda USL di Bologna
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vasopressin in septic shock, sponsored by Azienda USL di Bologna. Primary endpoint: Reduction in terms of the use of renal function replacement at 7 days. Started May 2024; status: recruiting.
02
Drugs
vasopressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06471231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471231.